At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 150 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)
In Brief
A Phase 4 clinical trial evaluating Pembrolizumab for Carcinoma, Non-Small-Cell Lung and Melanoma. Completed, enrolled 150 participants across 8 sites.
Detailed Summary
This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed cell death ligand 1 \[PD-L1\] ≥50%) or have experienced disease progression after a platinum-containing systemic therapy (PD-L1 ≥1%).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung, Melanoma
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartJan 2019
Primary CompletionAug 2024
TodayJul 2026
First PostedOct 23, 2018
Enrollment StartJan 31, 2019
Primary CompletionAug 21, 2024
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 7.7 years ago
Interventions
Pembrolizumabdrug
Administered as an intravenous (IV) infusion every 3 weeks (Q3W)